Back to search
FDAFDA · Food and drugs·Recall number Z-2068-2026

Mint Lesion; Software Versions: 3.4.0 up to 3.9.5.;

Published May 13, 2026 · Recall initiated: January 7, 2026

Summary

FDA records medical device Class II recall Z-2068-2026, published May 13, 2026 and initiated January 7, 2026. Recalling firm: Mint Medical GmbH; Status: Ongoing; Reported quantity: 101 systems; Lot: Software Versions: 3.4.0 up to 3.9.5. UDI-DI: 04260495880341, 04260495880358, 04260495880365, 04260495880372, 04260495880389, 04260495880396. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

If the connection between a mint Lesion workstation and the mint Lesion server is interrupted while performing a read, in rare cases some information may be lost or incorrectly linked to other patients.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mint Medical GmbH
Distributor
Worldwide distribution - US Nationwide and the countries of Germany, Switzerland, Austria, Belgium, Italy, France, Romania, Netherlands, United Kingdom, Spain, Czech Republic, Ireland, Poland;
Lot
Software Versions: 3.4.0 up to 3.9.5. UDI-DI: 04260495880341, 04260495880358, 04260495880365, 04260495880372, 04260495880389, 04260495880396.
Risk classification
Class II
Area (FDA)
device
Country
Germany

Related recalls

Questions about this recall

Was Mint Lesion; Software Versions: 3.4.0 up to 3.9.5.; recalled?

Yes. FDA published recall Z-2068-2026 on May 13, 2026. Reported hazard: If the connection between a mint Lesion workstation and the mint Lesion server is interrupted while performing a read, in rare cases some information may be lost or incorrectly linked to other patients.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail